Avibactam (Avycaz, Zavicefta)

Synonym(s): NXL104  |  AVE1330A

Class: Beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO])

Details of activity:	DBOs bind reversibly to the beta-lactamase in the active site, inhibits class A, C, D beta-lactamases. No intrinsic antibacterial activity
Combined with other compounds:	Yes
Description:	Synthetic compound. 2015 approved in fixed combination with ceftazidime. Orally available prodrug in clinical development, fixed combination with aztreonam in clinical development
Institute where first reported:	Sanofi-Aventis, Novexel, AstraZeneca, Pfizer, Abbvie (formerly Actavis, Allergan, Forest Laboratories)
Year first mentioned:	2002
Highest developmental phase:	Approved by FDA in 2015
Development status:	Approved

Chemical structure(s):
Canonical SMILES:	C1C[C@@H](C(=O)N)N2C[C@@H]1N(C2=O)OS(=O)(=O)O
Isomeric SMILES:	C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)N
InChI:	InChI=1S/C7H11N3O6S/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15/h4-5H,1-3H2,(H2,8,11)(H,13,14,15)/t4-,5+/m1/s1
InChI Key:	NDCUAPJVLWFHHB-UHNVWZDZSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/9835049

External links:
Guide to Pharmacology:	avibactam
Main Source:	https://pubmed.ncbi.nlm.nih.gov/15254025/
Citations:	https://pubmed.ncbi.nlm.nih.gov/32285965/ https://www.mdpi.com/2079-6382/10/8/1012/htm https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(16)30194-3/fulltext